Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer.

Liqiong Yang,Fan Xu,Jie Chen,Fangfang Liu,Xiechuan Weng,Yun Bai,Qing Li

doi:10.3389/fonc.2021.695645

Abstract

The prevalence of pancreatic cancer is sharply increasing recently, which significantly increases the economic burden of the population. At present, the primary treatment of resectable pancreatic cancer is surgical resection, followed by chemotherapy with or without radiation. However, the recurrence rates remain high even after R0 resection. This treatment strategy does not distinguish undetected metastatic disease, and it is prone to postoperative complications. Neoadjuvant therapies, including neoadjuvant chemotherapy and radiotherapy, is being increasingly utilized in borderline resectable as well as resectable pancreatic cancer. This review summarized and discussed clinical trials of neoadjuvant therapy for pancreatic cancer, comparing resection rates, outcome measures, and adverse reactions between neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy.

Highlights

Pancreatic cancer is one of the most common malignancies of the digestive tract, and one of the worst prognoses, with a 5-year survival rate of only 6% [1]
In 2019, Xiang et al evaluated the effect of the modified FOLFIRINOX regimen in patients with locally advanced pancreatic cancer (LAPC) in China, they found that patients who received mFOLFIRINOX and underwent surgery had the Microscopic margin negative positive positive highest progression-free survival (PFS) of 19.3 months and the higher overall survival (OS) of 27.7 months [19]
NEOADJUVANT THERAPY (NAT) improved the OS and PFS time of patients with a resectable pancreatic cancer compared with upfront surgery

Summary

Introduction

Pancreatic cancer is one of the most common malignancies of the digestive tract, and one of the worst prognoses, with a 5-year survival rate of only 6% [1]. Based on the GLOBOCAN 2020 estimates, pancreatic cancer has ranked the seventh most common cancer in the world counting 495,773 new cases and causing 466,003 deaths (4.7% of all deaths caused by cancer) in 2020 [2]. The incidence and mortality of pancreatic cancer increased with age, and it is most common in men [3]. The monthly medical expenses of pancreatic cancer patients are 15 times more than that of non-pancreatic cancer patients. It is important to plan potential new therapies to manage and control patient costs [4]

Methods

Results

Conclusion